Browsing Tag
Ambros Therapeutics
1 post
Can neridronate justify a $500m Ambros valuation after earlier Phase 3 setbacks?
Werewolf stock surges as a $150m Ambros merger funds neridronate through its pivotal 2028 CRPS-1 trial and planned FDA filing.